logo
Share SHARE
FONT-SIZE Plus   Neg

BioLineRx Announces Extension Of Patent For BCM By USPTO - Quick Facts

BioLineRx (BLRX) said an Issue Notification has been received from the United States Patent and Trademark Office granting 1,787 days of Patent Term Adjustment for the patent claiming the composition of BCM (BL-1040), a novel medical device for prevention of cardiac remodeling following an acute myocardial infarction.

Accordingly, the term of this patent will now extend through at least the end of April 2029, which is almost three years longer than previously reported by the company. Additional patents claiming the BL-1040 composition and its use for the treatment of ventricular remodeling and congestive heart failure due to acute myocardial infarction are granted or pending in Europe, Japan, Canada, Korea, Mexico, Israel, India, China and Australia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Procter & Gamble Co., (PG) Tuesday announced the promotion of David Taylor to the role of Chief Executive Officer, as the consumer goods giant replaces Chief Executive A.G. Lafley for the second time. David Taylor, a 35-year-veteran and currently Group President of Global Beauty, Grooming and Health... Anadarko Petroleum reported a plunge in second-quarter profit, hurt by weak oil prices, partly offset by some derivative gains. However, its earnings topped Street estimates, driven by operational efficiencies and sales of higher-margin oil. Anadarko shares... Micro-blogging site Twitter Inc said Tuesday after the markets closed that its second quarter net loss narrowed from last year, as revenue surged 61%. The company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
Follow RTT